SG11201510266SA - Dengue virus vaccine compositions and methods of use thereof - Google Patents
Dengue virus vaccine compositions and methods of use thereofInfo
- Publication number
- SG11201510266SA SG11201510266SA SG11201510266SA SG11201510266SA SG11201510266SA SG 11201510266S A SG11201510266S A SG 11201510266SA SG 11201510266S A SG11201510266S A SG 11201510266SA SG 11201510266S A SG11201510266S A SG 11201510266SA SG 11201510266S A SG11201510266S A SG 11201510266SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dengue virus
- vaccine compositions
- virus vaccine
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837721P | 2013-06-21 | 2013-06-21 | |
| PCT/US2014/042625 WO2014204892A1 (en) | 2013-06-21 | 2014-06-17 | Dengue virus vaccine compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201510266SA true SG11201510266SA (en) | 2016-01-28 |
Family
ID=52105172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201510266SA SG11201510266SA (en) | 2013-06-21 | 2014-06-17 | Dengue virus vaccine compositions and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9861692B2 (en) |
| EP (1) | EP3010536A4 (en) |
| JP (1) | JP2016523251A (en) |
| KR (1) | KR20160023683A (en) |
| CN (1) | CN105246506A (en) |
| AU (1) | AU2014281713A1 (en) |
| BR (1) | BR112015031226A2 (en) |
| MX (1) | MX366154B (en) |
| MY (1) | MY187896A (en) |
| PH (1) | PH12015502666A1 (en) |
| SG (1) | SG11201510266SA (en) |
| WO (1) | WO2014204892A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3236997A4 (en) | 2014-12-22 | 2018-05-30 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| US10105434B2 (en) | 2015-08-03 | 2018-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Immune enhancing recombinant dengue protein |
| WO2017056101A1 (en) * | 2015-09-30 | 2017-04-06 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
| WO2018217906A1 (en) * | 2017-05-23 | 2018-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus serotype 4 epitopes |
| CN117752780A (en) | 2017-12-07 | 2024-03-26 | 默沙东有限责任公司 | Formulations of dengue virus vaccine compositions |
| CN111346079B (en) * | 2020-02-24 | 2023-06-20 | 南方医科大学 | Bacterial DNA gyrase inhibitor BRD7716 as medicament for treating and/or preventing dengue virus infection and pharmaceutical application thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
| NZ337522A (en) | 1997-02-28 | 2001-02-23 | St | Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses |
| ATE321567T1 (en) | 1997-07-31 | 2006-04-15 | Hawaii Biotech Inc | RECOMBINANT DIMERIC ENVELOPE PROTEINS AS A VACCINE AGAINST A FLAVIVIRAL INFECTION |
| DE69942525D1 (en) | 1998-09-02 | 2010-08-05 | Us Government | DENGUE VIRUSES NOT REPLICATED IN MOSQUITOS FOR USE AS A VACCINE |
| EP1165127B1 (en) | 1999-03-26 | 2008-12-31 | Walter Reed Army Institute of Research | Multivalent dengue virus vaccine |
| EP1165131A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-1 virus vaccine |
| EP1165128A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-2 virus vaccine |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| DK2290108T3 (en) | 2001-05-22 | 2014-10-20 | Us Gov Health & Human Serv | Development of mutations useful in attenuating dengue viruses as well as chimeric dengue viruses |
| ES2924640T3 (en) | 2002-01-15 | 2022-10-10 | Sanofi Pasteur Biologics Llc | flavivirus vaccines |
| ES2677348T3 (en) | 2002-05-03 | 2018-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A recombinant chimeric dengue virus rDEN3 / 4delta 30 (ME), rDEN2 / 4delta30 (ME) or rDEN1 / 4delta30 (ME) that contains a deletion of 30 nucleotides (delta30) in a section of the 3 'non-translated region of the genome of type 4 dengue, wherein said 30 nucleotide deletion corresponds to the stem-loop structure of TL2 |
| WO2003101397A2 (en) * | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| EA015907B1 (en) | 2004-10-20 | 2011-12-30 | Санофи Пастер Байолоджикс Ко. | Recombinant flavivirus and use thereof |
| BRPI0613287A2 (en) | 2005-06-17 | 2010-12-28 | Sanofi Pasteur | live attenuated dengue-2 virus strain, immunogenic composition, vaccine composition, isolated nucleic acid, isolated polyprotein encoded by sequence id. 1 or fragments thereof and polyprotein fragment |
| KR101536612B1 (en) | 2005-06-17 | 2015-07-14 | 사노피 파스퇴르 | Dengue serotype 1 attenuated strain |
| JP5193856B2 (en) | 2005-06-24 | 2013-05-08 | インターベツト・インターナシヨナル・ベー・ベー | Inactivated chimeric vaccine and related methods of use |
| WO2007015783A2 (en) | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| AR061197A1 (en) | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | DENGUE VIRUS 3 CEPAS VIVAS ATENUADAS |
| DK2589602T3 (en) | 2006-08-15 | 2016-07-25 | The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of | Development of dengue virus vaccine components |
| FR2906724B1 (en) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE. |
| WO2008127307A2 (en) | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| FR2909286B1 (en) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE |
| BRPI0904020B8 (en) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | vaccine composition against the dengue virus, and kit |
| BR112013009649A2 (en) * | 2010-10-29 | 2016-07-12 | Merck Sharp & Dohme | immunogenic composition, methods for eliciting a protective immune response in a human patient and for providing human immune protection against disease, and use of a composition |
| PE20150356A1 (en) | 2012-07-24 | 2015-03-20 | Sanofi Pasteur | VACCINE COMPOSITIONS FOR THE PREVENTION AGAINST INFECTION BY DENGUE VIRUS |
-
2014
- 2014-06-17 WO PCT/US2014/042625 patent/WO2014204892A1/en active Application Filing
- 2014-06-17 KR KR1020157035588A patent/KR20160023683A/en not_active Application Discontinuation
- 2014-06-17 BR BR112015031226A patent/BR112015031226A2/en not_active Application Discontinuation
- 2014-06-17 US US14/898,515 patent/US9861692B2/en active Active
- 2014-06-17 JP JP2016521494A patent/JP2016523251A/en active Pending
- 2014-06-17 CN CN201480031059.5A patent/CN105246506A/en active Pending
- 2014-06-17 MY MYPI2015002912A patent/MY187896A/en unknown
- 2014-06-17 AU AU2014281713A patent/AU2014281713A1/en not_active Abandoned
- 2014-06-17 MX MX2015017384A patent/MX366154B/en active IP Right Grant
- 2014-06-17 EP EP14814205.2A patent/EP3010536A4/en not_active Withdrawn
- 2014-06-17 SG SG11201510266SA patent/SG11201510266SA/en unknown
-
2015
- 2015-11-27 PH PH12015502666A patent/PH12015502666A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160151477A1 (en) | 2016-06-02 |
| PH12015502666B1 (en) | 2016-03-07 |
| BR112015031226A2 (en) | 2017-08-29 |
| EP3010536A1 (en) | 2016-04-27 |
| KR20160023683A (en) | 2016-03-03 |
| EP3010536A4 (en) | 2016-11-30 |
| MX366154B (en) | 2019-06-28 |
| AU2014281713A1 (en) | 2015-11-12 |
| MY187896A (en) | 2021-10-27 |
| JP2016523251A (en) | 2016-08-08 |
| US9861692B2 (en) | 2018-01-09 |
| CN105246506A (en) | 2016-01-13 |
| WO2014204892A1 (en) | 2014-12-24 |
| PH12015502666A1 (en) | 2016-03-07 |
| MX2015017384A (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214962A1 (en) | Influenza virus immunogenic compositions and uses thereof | |
| HK1223016A1 (en) | Adeno-associated virus variants and methods of use thereof | |
| SI3071696T1 (en) | C/ebp alpha short activating rna compositions and methods of use | |
| EP2964235A4 (en) | Antimicrobial-antibiofilm compositions and methods of use thereof | |
| SG11201606624WA (en) | Antibody moleules to dengue virus and uses thereof | |
| HK1223110A1 (en) | Influenza virus vaccines and uses thereof | |
| IL265876A (en) | Compositions comprising 15-ohepa and methods of using the same | |
| HK1225645A1 (en) | Pcv2b divergent vaccine composition and methods of use | |
| IL240227A0 (en) | Immunogenic compositions comprising silicified virus and methods of use | |
| HK1221641A1 (en) | Vaccine composition and method of use | |
| EP2897639A4 (en) | Improved vaccine compositions and methods of use | |
| IL239840A0 (en) | Polymyxins, compositions, methods of making and methods of use | |
| SG11201604523SA (en) | Insect repellent compositions and methods of use | |
| SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| EP3022298A4 (en) | Attenuated influenza vaccines and uses thereof | |
| SG11201510617WA (en) | Methods and compositions for dengue virus vaccines | |
| SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| SG11201505930TA (en) | Porcine parvovirus 5b, methods of use and vaccine | |
| HK1216395A1 (en) | E1e2 hcv vaccines and methods of use e1e2 hcv | |
| IL244537A0 (en) | Novel delivery compositions and methods of using same | |
| HK1219904A1 (en) | Novel vaccines against multiple subtypes of dengue virus | |
| HK1216006A1 (en) | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof | |
| ZA201603800B (en) | Insect repellent compositions and methods of use | |
| IL243769A0 (en) | Short peptides derived from vdac1, compositions and methods of use thereof | |
| TH181994B (en) | Divergent PCV2B Vaccine Composition And how to use it |